Acetylon Pharmaceuticalsâ Selective HDAC Inhibitors in Multiple Myeloma, Lymphoma and Sickle Cell Disease and Î²-Thalassemia to Be Featured in 11 Presentations at the American Society of Hematology Annual Meeting